POC

Global Synthetic Biology, Logic Gated Therapies, Rapid Molecular Diagnostics & Peptide Synthesis Platforms Report 2022 - Featuring Arsenalbio, Beam Therapeutics, Circuit Bio and Genes2Me Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 5, 2022
Health, Biotechnology, Synthetic biology, Pain, Innovation, Regenerative medicine, Ministry of Health & Wellness, Disease management, Health, DNA, Genetic engineering, COVID-19 testing, Wellness, POC, Nanomedicine, List of life sciences, Biomarker, COVID-19, Drug discovery, Industry, Tissue engineering, Fine chemical, Pharmaceutical industry

The "Growth Opportunities in Synthetic Biology, Logic Gated Therapies, Rapid Molecular Diagnostics and Peptide Synthesis Platforms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Synthetic Biology, Logic Gated Therapies, Rapid Molecular Diagnostics and Peptide Synthesis Platforms" report has been added to ResearchAndMarkets.com's offering.
  • This report focuses on synthetic biology innovations around low cost gene synthesis and deployment of gene circuits for drug discovery and in therapies.
  • Cell and gene therapies using logic gated circuits, along with early stage developers of gene circuits for drug discovery applications are covered.
  • A rapid and sensitive molecular diagnostic for scalable Covid-19 testing, which can be adapted at PoC has also been discussed.

In Vitro Diagnostics Market Size Worth $113.38 Billion by 2030 - Grand View Research, Inc.

Retrieved on: 
Monday, September 5, 2022
Partnership, Reagent, CVD, COVID-19, Technology, Cancer, Application, SAN, Genetic testing, USD, Infection, Diagnosis, Degenerative disease, POC, Severe acute respiratory syndrome coronavirus 2, PCR, Prevalence, CAGR, Hospital, Instrument, Adoption, Nature, Pharmaceutical industry, Medical device, Cryptocurrency, Texas Homecare

SAN FRANCISCO, Sept. 5, 2022 /PRNewswire/ -- The global in vitro diagnostics market size is expected to reach USD 113.38 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Sept. 5, 2022 /PRNewswire/ -- The global in vitro diagnostics market size is expected to reach USD 113.38 billion by 2030, according to a new report by Grand View Research, Inc.
  • Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers.
  • Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.
  • Read 200-page market research report, " In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents, Services), By Test Location (PoC, Homecare), By End-use (Hospitals, Laboratory), By Application, By Technology, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.

Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® Flu Molecular Test

Retrieved on: 
Thursday, September 1, 2022
Cue, Mayo Clinic, UPMC Children's Hospital of Pittsburgh, COVID-19, EUA, CEO, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Hand, SAN, Central Drugs Standard Control Organisation, Federal Food, Drug, and Cosmetic Act, Johns Hopkins School of Medicine, Major League Baseball, Virus, Risk, National Basketball Association, Food, Bluetooth, Diagnosis, Union, Interim order, Health Canada, SEC, De novo, Multimedia, Emergency Use Authorization, National, Severe acute respiratory syndrome coronavirus 2, PCR, Hospital, Nasdaq, FDA, Bridgewater, Annual report, Compte rendu, POC, CE, PSAR, Health Sciences Authority, Health, Patient, Pharmaceutical industry, Google

FDA clearance of Cue's test would provide the public, for the first time, an at-home and POC molecular flu test that has been fully reviewed by the FDA for safety and effectiveness.

Key Points: 
  • FDA clearance of Cue's test would provide the public, for the first time, an at-home and POC molecular flu test that has been fully reviewed by the FDA for safety and effectiveness.
  • Clinical study results with the Cue Flu Molecular Test were favorable, demonstrating 99% accuracy1compared to FDA cleared molecular (PCR) laboratory tests for influenza A&B.
  • The Cue Flu Molecular Test cartridge uses a lower nasal swab and is compatible with the Cue Reader, which communicates test results digitally via Bluetooth to a mobile device in approximately 25 minutes.
  • "This FDA submission for our Cue Flu Molecular Test is another important milestone on Cue's path to pioneer a new approach to diagnostics in homes, enterprises, and healthcare settings," said Ayub Khattak, Chairman and CEO of Cue Health.

INNOVATIVE ASIAN OATMEAL YISHI FOODS LAUNCHES NATIONWIDE IN WHOLE FOODS MARKET

Retrieved on: 
Thursday, September 1, 2022
The Non-GMO Project, CEO, Bon Appétit, Veganism, Central Market, Whole Foods Market, Bristol Farms, USDA, Multimedia, Yishi Jin, Snack, Instagram, Organic, Publication, Paleolithic diet, Founder, POC, Taste, Gelson, Coffee, Online shopping, TikTok, Forbes, New York (magazine)

CHICAGO, Sept. 1, 2022 /PRNewswire/ --  Yishi Foods, a Chicago-based maker of Asian-inspired oatmeals, today announced it has expanded distribution to all U.S. Whole Foods Markets locations, totalling over 500 stores.

Key Points: 
  • Award-winning Asian-inspired oatmeal hits shelves in all Whole Foods Market stores across the United States in time for fall and back-to-school season.
  • CHICAGO, Sept. 1, 2022 /PRNewswire/ -- Yishi Foods , a Chicago-based maker of Asian-inspired oatmeals, today announced it has expanded distribution to all U.S.
  • Founded by Chinese immigrant Lin Jiang in 2019, Yishi is inspired by the childhood memories of her mother's homemade breakfast porridge.
  • Launched in 2019 by Chinese immigrant and former consultant Lin Jiang, Yishi Foods is a first-of-its-kind breakfast brand celebrating traditional and modern Asian ingredients.

COVID-19 Will Be With Us For Years, So Will a Large In Vitro Diagnostics Market

Retrieved on: 
Wednesday, August 31, 2022
BD (company), COVID-19, Science, Cancer, HPV, Publication, Immunohistochemistry, Disease, Carlson, Alere, AACC, Cepheid variable, Abbott, Molecular Cancer Research, DNA, IVD, Infection, Multimedia, Yale University, Roche, Severe acute respiratory syndrome coronavirus 2, COVID-19 testing, PSAS, Yale Daily News, Non-functional testing, Siemens Healthineers, Risk, Diabetes, Terminology, POC, Acquisition, Industry, Growth, COVID, Patient, Fine chemical, Pharmaceutical industry, Vaccine, Medical device, Quidel Corporation, Kalorama

 ARLINGTON, Va., Aug. 31, 2022 /PRNewswire/ -- The worldwide in vitro diagnostic (IVD) market will reach $127.4 billion dollars in 2022, according to IVD market research firm Kalorama Information.  That's the finding from the firm's 15th large-scale IVD industry report, The Worldwide Market for In Vitro Diagnostic Tests, released this month. The market will grow to $140.1 billion in 2027, and COVID-19 testing will drive that market. The larger part of the IVD market is non-COVID testing and diabetes and cancer testing products, which will also drive the industry to growth.  

Key Points: 
  • That's the finding from the firm's 15th large-scale IVD industry report, The Worldwide Market for In Vitro Diagnostic Tests , released this month.
  • The market will grow to $140.1 billion in 2027, and COVID-19 testing will drive that market.
  • Kalorama has called the IVD market for two decades in detailed reports based on company financial information, interviews and medical statistics (FOR MORE INFORMATION: https://kaloramainformation.com/product/the-worldwide-market-for-in-vitr... ).
  • But the bulk of the market sales in 2022, an estimated $94.8 billion, will be from non-COVID-19 IVD tests.

Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors

Retrieved on: 
Wednesday, August 31, 2022
Lazarus, Health care, VP, Security (finance), Private practice, CEO, Analyser, OTCQB, CRP, SAN, Elab, Time, Ross University School of Medicine, Decision-making, C-reactive protein, North American Medical Management, Board, Medicine, Point-of-care testing, Bureau of Oceans and International Environmental and Scientific Affairs, Qiagen, Forward-looking statement, Medical degree, Medication, U.S. Securities and Exchange Commission, Organization, Procalcitonin, Point of care, GLOBE, PCT, Leadership, Company, MHRA, Marlboro College, Public policy, Roche Diagnostics, Sepsis, Biochemistry, Diabetes, Director, POC, CE, Industry, Physiology, Growth, LAC, Health, Management, Medical device, Science, MD

We are extremely pleased to welcome Tadd S. Lazarus, M.D., to the board and leadership of the Company, said Dr. Thomas Schlumpberger, CEO of Nanomix.

Key Points: 
  • We are extremely pleased to welcome Tadd S. Lazarus, M.D., to the board and leadership of the Company, said Dr. Thomas Schlumpberger, CEO of Nanomix.
  • Dr. Lazarus brings an important medical and industry perspective to the Nanomix Board, said Garrett Gruener, Chairman of the Nanomix Board of Directors.
  • Tadds input and counsel will be very valuable as we accelerate our commercial efforts and broaden our product portfolio.
  • I am thrilled about working with the Nanomix team to fully develop the exciting eLab mobile diagnostics testing platform.

Global Blood Gas and Electrolyte Analyzers Market Report 2022: Industry Witnesses Inflow of Sophisticated Solutions - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022
Biotechnology, Health, Medical Devices, COVID-19, Nicu Ceaușescu, Technology, Nitrogen, Electrolyte, ED, Countertop, CCU, Hospital, POC, High-dependency unit, Urea, CAGR, Trauma, Growth, Automation, Creatinine, ICU, Adoption, Patient, Medical device

The "Blood Gas and Electrolyte Analyzers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Gas and Electrolyte Analyzers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Another driver for the global market is increasing adoption of these devices across hospitals, emergency wards and diagnostic centers.
  • Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
  • Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing.

LeddarTech Is Recognized With Two Prestigious Awards for Its Raw Data Sensor Fusion and Perception ADAS and AD Platform

Retrieved on: 
Wednesday, August 31, 2022
Software, XLrator Media, Level 5, Technology, CEO, 3D, Safety, SAE, Perception, Solution, Electronics, Organization, Quality of life, POC, Volkswagen Group, ADAS, GLOBE, Tier, SOC, Lidar, Algorithm, AD, Association, Name, Industry, AI, Leddar, 3D printing

QUEBEC CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) -- LeddarTech , a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, proudly announces receiving two awards recognizing its LeddarVision sensor fusion and perception platform.

Key Points: 
  • QUEBEC CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) -- LeddarTech , a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, proudly announces receiving two awards recognizing its LeddarVision sensor fusion and perception platform.
  • We were impressed by LeddarTechs professionally prepared pitch and proposal of a PoC, stated Jan Zawadzki, Head of AI, CARIAD .
  • LeddarTech received this award for its highly innovative raw data sensor fusion and perception technology that enhances ADAS and AD safety over traditional object fusion technology.
  • This commitment to a safer and more customer-centric sensor fusion and perception software solution sets LeddarTech apart, leading to being selected for this prestigious award.

Global Urinary Tract Infection Testing Market Report (2022 to 2030) - Size, Share & Trends Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Health, General Health, International Diabetes Federation, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, NCBI, Urinary tract infection, Human services, Ageing, Awareness, Urology, IDF, Scope, Man, Recurrence, Incidence, Physician, Diabetes, UTI, Investment, POC, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Prevalence, Pyelonephritis, Adult, Risk, Woman, Growth, Industry, Life, Adoption, Pharmaceutical industry, Medical imaging

Urinary tract infection is becoming a common global concern.

Key Points: 
  • Urinary tract infection is becoming a common global concern.
  • According to research studies, UTI occurs in one in five adult women at some point in their life.
  • Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000.
  • This can be attributed to better reimbursement facilities and a rise in the adoption of novel diagnostic products due to increased awareness
    Chapter 3 Urinary Tract Infection Market Variables, Trends, and Scope

NICE Interaction Analytics Chosen by Tele-Centre Services to Drive Customer Experience Interactions (CXi) Transformation

Retrieved on: 
Tuesday, August 30, 2022
Data Management, Technology, Professional Services, Other Communications, Marketing, Communications, Other Technology, Digital Marketing, Apps, Applications, Data Analytics, Software, COVID-19, Technology, Diversion airport, NICE Ltd., Solution, CX, Risk, NICE, Forward-looking statement, SEC, Organization, U.S. Securities and Exchange Commission, Company, BPO, Marketing, POC, Private Securities Litigation Reform Act, Growth, Nice International Tournament, Adoption, Sales

Employing NICE Interaction Analytics provides Tele-Centre the ability to understand customer insights to enhance overall customer satisfaction and help drive business process transformation.

Key Points: 
  • Employing NICE Interaction Analytics provides Tele-Centre the ability to understand customer insights to enhance overall customer satisfaction and help drive business process transformation.
  • The deployment of NICE Interaction Analytics allows Tele-centre to provide analytics-focused, data-driven insights to key private and government organizations.
  • Nicholas Loh, Managing Director, Tele-Centre, said NICEs Interaction Analytics analyzes every interaction and provides insights on customers and agents behavior for more effective coaching conversations that improve the customer experience.
  • Our goal is to be number one from a customer experience standpoint and I believe we are well equipped to reach that goal with NICE Interaction Analytics and Quality Central.